PT778023E - Agentes neuroprotectores - Google Patents

Agentes neuroprotectores

Info

Publication number
PT778023E
PT778023E PT96308786T PT96308786T PT778023E PT 778023 E PT778023 E PT 778023E PT 96308786 T PT96308786 T PT 96308786T PT 96308786 T PT96308786 T PT 96308786T PT 778023 E PT778023 E PT 778023E
Authority
PT
Portugal
Prior art keywords
neuroprotector
agents
neuroprotector agents
Prior art date
Application number
PT96308786T
Other languages
English (en)
Inventor
Stephen Shi-Hsun Lin
Katherine Lu Molnar-Kimber
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PT778023E publication Critical patent/PT778023E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT96308786T 1995-12-07 1996-12-04 Agentes neuroprotectores PT778023E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US833795P 1995-12-07 1995-12-07

Publications (1)

Publication Number Publication Date
PT778023E true PT778023E (pt) 2003-06-30

Family

ID=21731060

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96308786T PT778023E (pt) 1995-12-07 1996-12-04 Agentes neuroprotectores

Country Status (23)

Country Link
EP (1) EP0778023B1 (pt)
JP (1) JPH09183727A (pt)
KR (1) KR970032856A (pt)
CN (1) CN1112925C (pt)
AR (1) AR008747A1 (pt)
AT (1) ATE234095T1 (pt)
AU (1) AU700653B2 (pt)
BR (1) BR9605895A (pt)
CA (1) CA2192298A1 (pt)
CZ (2) CZ6498A3 (pt)
DE (1) DE69626610T2 (pt)
DK (1) DK0778023T3 (pt)
ES (1) ES2188730T3 (pt)
HU (1) HUP9603370A3 (pt)
IL (1) IL119778A (pt)
MX (1) MX9606131A (pt)
NO (1) NO309966B1 (pt)
NZ (1) NZ299888A (pt)
PT (1) PT778023E (pt)
SI (1) SI0778023T1 (pt)
SK (1) SK154796A3 (pt)
TW (1) TW427904B (pt)
ZA (1) ZA9610245B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002535A1 (en) 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
AU2001255406A1 (en) * 2000-04-17 2001-10-30 Gpi Nil Holdings, Inc. Cyclic diaza compounds for treating neurodegenerative disorders
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
EP1622625A1 (en) * 2003-04-09 2006-02-08 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o] non-1 (7)-en-2-yl )alkyl] phosphonic acid and derivatives and methods of use thereof
EP1611144B1 (en) 2003-04-09 2010-09-15 Wyeth LLC Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
WO2004089369A2 (en) * 2003-04-11 2004-10-21 Cambridge University Technical Services Limited Methods and means for treating protein conformational disorders
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
GT200400213A (es) 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
DK1828202T3 (da) * 2004-12-20 2012-05-07 Wyeth Llc Rapamycinanaloge samt deres anvendelse ved behandling af neurologiske, proliferative og inflammatoriske lidelser
US7273874B2 (en) 2004-12-20 2007-09-25 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
KR20130128018A (ko) * 2009-04-10 2013-11-25 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2456437A4 (en) * 2009-07-24 2013-01-09 Inst Nat Rech Scient COMBINATION THERAPY FOR TAUOPATHIES
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9121859B2 (en) * 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
LT3003268T (lt) 2013-06-05 2018-12-10 Pharnext Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api)
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
WO2019099671A1 (en) * 2017-11-15 2019-05-23 Vanderbilt University Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease
CN114366738A (zh) * 2021-12-20 2022-04-19 中国人民解放军军事科学院军事医学研究院 雷帕霉素在促进神经干细胞扩增中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5260299A (en) * 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
DK0778023T3 (da) 2003-06-30
IL119778A (en) 1999-07-14
CN1159915A (zh) 1997-09-24
MX9606131A (es) 1997-08-30
CZ354496A3 (cs) 1998-03-18
JPH09183727A (ja) 1997-07-15
ZA9610245B (en) 1998-06-05
SK154796A3 (en) 1997-09-10
ATE234095T1 (de) 2003-03-15
CZ6498A3 (cs) 1998-06-17
NO309966B1 (no) 2001-04-30
BR9605895A (pt) 1998-08-18
TW427904B (en) 2001-04-01
AU7417896A (en) 1997-06-12
ES2188730T3 (es) 2003-07-01
NZ299888A (en) 2001-02-23
EP0778023A1 (en) 1997-06-11
CN1112925C (zh) 2003-07-02
DE69626610T2 (de) 2003-10-02
AR008747A1 (es) 2000-02-23
SI0778023T1 (en) 2003-08-31
DE69626610D1 (de) 2003-04-17
CA2192298A1 (en) 1997-06-08
HUP9603370A3 (en) 1998-12-28
IL119778A0 (en) 1997-03-18
NO965238D0 (no) 1996-12-06
HUP9603370A2 (en) 1997-05-28
HU9603370D0 (en) 1997-01-28
EP0778023B1 (en) 2003-03-12
AU700653B2 (en) 1999-01-14
KR970032856A (ko) 1997-07-22
NO965238L (no) 1997-06-09

Similar Documents

Publication Publication Date Title
PT778023E (pt) Agentes neuroprotectores
DE69621528D1 (de) Anti-inflamatorische agenzien
NO981133D0 (no) Ikke-reseptormedierte kontrastmidler
PT828506E (pt) Agentes endoparasiticidas
DE69627723T2 (de) Narkosemittelverdunster
ATA135896A (de) Skibob
ATE198470T1 (de) Alkenyl-benzoylguanidine
FI950335A (fi) Hätäkutsulaite
ATE240972T1 (de) Cyclopeptolide
DE69528289T2 (de) Rasentraktor
FI951740A0 (fi) Djupdragningsanordning foer plastprodukter
DE29520895U1 (de) Felgen-Reifenkombination
DE29508049U1 (de) Reling-Leuchten-Kombination
BR9503669A (pt) Traduções em cruzadas
FI950743A0 (fi) Bioimmunoterapeutisk kombination
DE29514383U1 (de) Spinner-Streamer-Kombination
SE9501634D0 (sv) Burkback
FI955570A0 (fi) Seen
FI954223A (fi) Sähk¦staattisesti kontrolloitu kappale
FI2033U1 (fi) Dragdon
SE9501165D0 (sv) Hållaranordning
BR7500825U (pt) Chutegol
BR9500075A (pt) Carrapetilha
BR7501298U (pt) Torre-audio-visual
BR7501299U (pt) Geladeira-prática